Database→5-Amino-1MQ

Tier 4Fat LossMetabolicLongevityPREMIUM

5-Amino-1MQ

5-Amino-1-Methylquinolinium (5-Amino-1MQ; 5A1MQ; NNMT Inhibitor)

Not FDA-approved for any indication. Not a licensed drug. Sold as research chemical only; not for human use. No approved drug status in any jurisdiction. Not explicitly listed on the 2026 WADA Prohibited List by name; could fall under S0 (non-approved substances) or S2 catch-all provisions depending on interpretation. No compounding authorization. No IND on file for human trials.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

5-Amino-1MQ (5-Amino-1-Methylquinolinium) is a synthetic small molecule NNMT inhibitor, not a peptide, included in this series because it circulates widely in peptide research contexts. NNMT (nicotinamide N-methyltransferase) methylates nicotinamide, depleting NAD+ precursors and consuming SAM. Inhibiting NNMT raises intracellular NAD+, elevates SAM, and suppresses lipogenesis in adipocytes. The Neelakantan 2018 mouse study (11 days, diet-induced obese) showed significant fat mass and body weight reduction without food intake changes. Babula 2024 (28 days, diet-induced obese mice) confirmed dose-dependent fat mass limitation, improved insulin sensitivity, and attenuated hepatic steatosis, while also identifying MAO-A inhibition as an off-target activity. Dimet-Wiley 2024 (aged mice, 8 weeks) showed approximately 40% greater grip strength in NNMT-inhibitor-treated sedentary mice versus controls. No human clinical trial has been published.

🔒

Full Profile: Premium Members Only

The complete 5-Amino-1MQ profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use